+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Alzheimer's Therapeutics Market Size, Share & Trends Analysis By Product (Cholinesterase Inhibitors, NMDA Receptor Antagonist, Combination Drug, Pipeline Drugs), By End-user, By Region, And Segment Forecasts, 2023-2030

  • PDF Icon

    Report

  • 103 Pages
  • June 2023
  • Region: Global
  • Grand View Research
  • ID: 5644963
Description Jump to:
The global Alzheimer’s therapeutics market size is expected to reach USD 15.19 billion by 2030, according to this report. The market is expected to expand at a CAGR of 19.99% from 2023 to 2030. Government organizations are engaged in providing funds for Alzheimer's support, care, and research activities, which is projected to fuel the market growth. For instance, in March 2022, the Alzheimer's Society announced to spend around USD 3.5 billion in the coming years on dementia research to improve the care of patients.

Additionally, the Alzheimer's Association with the Alzheimer's Impact Movement (AIM) announced to utilize USD 25 million to implement the BOLD Infrastructure for Alzheimer's Act to create an effective public health substructure for patients. In addition, in September 2021, the South Texas Alzheimer's Disease Center and the Duke/University of North Carolina Alzheimer's Disease Research Center were granted USD 14.8 million over five years by the National Institute of Aging to encourage research on risk factors related to AD.

Furthermore, an increase in the incidence and cost burden of dementia associated with AD is expected to boost the market growth. According to the Alzheimer's Society, around 900,000 people are living with dementia in the United Kingdom, and it is projected to rise to 1.6 million by 2040 and the incidence of dementia will be 209,600 in the same year.

The current standard of care is limited to symptom-relieving drugs. Therefore, the approval of disease-modifying anti-amyloid therapeutics is expected to change the treatment landscape. For instance, in June 2021, the U.S. FDA granted accelerated approval to Aduhelm (aducanumab) for the treatment of patients with Alzheimer’s disease. It is a monoclonal antibody that targets cluster forms of amyloid beta present in the brains of patients and stops its formation. Other key anti-amyloid monoclonal antibodies in late-stage clinical trials include Gantenerumab (F. Hoffmann-La Roche Ltd.), Solanezumab (Eli Lilly and Company), and Lecanemab (Eisai Inc./Biogen), among others.

Alzheimer's Therapeutics Market Report Highlights

  • By product, the cholinesterase inhibitors segment held the largest revenue share in 2022 as it is the current standard of care. In March 2022, the U.S. FDA approved the cholinesterase inhibitor Adlarity (donepezil hydrochloride) developed by Corium Inc. for the treatment of patients with AD
  • Pipeline drugs are anticipated to witness the fastest growth over the forecast period due to the presence of a strong product pipeline and their expected launch during the forecast period. Biogen’s product lecanemab (BAN2401), an anti-amyloid beta protofibril antibody for treating AD, is currently in phase 3 clinical trials
  • The hospital pharmacy end-user segment dominated the market in 2022 owing to the high hospitalization rate. According to Alzheimer’s Association report 2022, approximately 32% of total Medicare beneficiaries with Alzheimer’s have at least one hospital discharge annually

Table of Contents

Chapter 1. Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Segment Definitions
1.1.1.1 Product Segment
1.1.1.2 End-User Segment
1.2 Regional Scope
1.3 Estimates And Forecast Timeline
1.4 Objectives
1.4.1 Objective - 1
1.4.2 Objective - 2
1.4.3 Objective - 3
1.5 Research Methodology
1.6 Information Procurement
1.6.1 Purchased Database
1.6.2 Gvr’s Internal Database
1.6.3 Secondary Sources
1.6.4 Primary Research
1.7 Information Or Data Analysis
1.7.1 Data Analysis Models
1.8 Market Formulation & Validation
1.9 Model Details
1.9.1 Commodity Flow Analysis
1.10 List Of Secondary Sources
1.11 List Of Abbreviations
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation And Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends And Outlook
3.4. Market Dynamics
3.4.1. Increasing Prevalence Of Alzheimer’s Disease
3.4.2. Presence Of Strong Pipeline Drugs For Alzheimer’s Disease
3.4.3. Introduction Of Innovative Technologies
3.4.4. Increase In Government Funding And Initiatives
3.4.5. Increase In Awareness Programs
3.5. Market Restraint Analysis
3.5.1. Presence Of Stringent Regulatory Framework
3.5.2. High Clinical Trial Failures
3.6. Business Environment Analysis
3.6.1. Swot Analysis; By Factor (Political & Legal, Economic And Technological)
3.6.2. Porter’s Five Forces Analysis
Chapter 4. Product Business Analysis
4.1 Alzheimer’s Therapeutics Market: Drug Class Movement Analysis
4.1.1 Cholinesterase Inhibitors
4.1.1.1 Cholinesterase Inhibitors Market Estimates And Forecast, 2018 - 2030
4.1.1.1.1 Donepezil Inhibitors Market Estimates And Forecast, 2018 - 2030
4.1.1.1.2 Galantamine Inhibitors Market Estimates And Forecast, 2018 - 2030
4.1.1.1.3 Rivastigmine Inhibitors Market Estimates And Forecast, 2018 - 2030
4.1.2 N-Methyl-D-Aspartate (Nmda) Receptor Antagonist
4.1.2.1 N-Methyl-D-Aspartate (Nmda) Receptor Antagonist Market Estimates And Forecast, 2018 - 2030
4.1.3 Combination Drug
4.1.3.1 Combination Drug Market Estimates And Forecast, 2018 - 2030
4.1.4 Pipeline Drugs
4.1.4.1 Pipeline Drugs Market Estimates And Forecast, 2018 - 2030
Chapter 5. End User Business Analysis
5.1 Alzheimer’s Therapeutics Market: End User Movement Analysis
5.1.1 Hospital Pharmacy
5.1.1.1 Hospital Pharmacy Market Estimates And Forecast, 2018 - 2030
5.1.2 Retail Pharmacy
5.1.2.1 Retail Pharmacy Market Estimates And Forecast, 2018 - 2030
5.1.3 E-Commerce
5.1.3.1 E-Commerce Market Estimates And Forecast, 2018 - 2030
Chapter 6. Regional Business Analysis
6.1. Alzheimer’s Therapeutics Market Share By Region, 2022 & 2030
6.2. North America
6.2.1. Swot Analysis
6.2.2. North America Alzheimer’s Therapeutics Market, 2018 - 2030 (Usd Million)
6.2.3. U.S.
6.2.3.1. Key Country Dynamics
6.2.3.2. Target Disease Prevalence
6.2.3.3. Competitive Scenario
6.2.3.4. Regulatory Framework
6.2.3.5. Reimbursement Scenario
6.2.3.6. U.S. Alzheimer’s Therapeutics Market, 2018 - 2030 (Usd Million)
6.2.4. Canada
6.2.4.1. Key Country Dynamics
6.2.4.2. Target Disease Prevalence
6.2.4.3. Competitive Scenario
6.2.4.4. Regulatory Framework
6.2.4.5. Reimbursement Scenario
6.2.4.6. Canada Alzheimer’s Therapeutics Market, 2018 - 2030 (Usd Million)
6.3. Europe
6.3.1. Swot Analysis
6.3.2. Europe Alzheimer’s Therapeutics Market, 2018 - 2030 (USD Million)
6.3.3. Germany
6.3.3.1. Key Country Dynamics
6.3.3.2. Target Disease Prevalence
6.3.3.3. Competitive Scenario
6.3.3.4. Regulatory Framework
6.3.3.5. Reimbursement Scenario
6.3.3.6. Germany Alzheimer’s Therapeutics Market, 2018 - 2030 (USD Million)
6.3.4. UK
6.3.4.1. Key Country Dynamics
6.3.4.2. Target Disease Prevalence
6.3.4.3. Competitive Scenario
6.3.4.4. Regulatory Framework
6.3.4.5. Reimbursement Scenario
6.3.4.6. UK Alzheimer’s Therapeutics Market, 2018 - 2030 (USD Million)
6.3.5. France
6.3.5.1. Key Country Dynamics
6.3.5.2. Target Disease Prevalence
6.3.5.3. Competitive Scenario
6.3.5.4. Regulatory Framework
6.3.5.5. Reimbursement Scenario
6.3.5.6. France Alzheimer’s Therapeutics Market, 2018 - 2030 (USD Million)
6.3.6. Italy
6.3.6.1. Key Country Dynamics
6.3.6.2. Target Disease Prevalence
6.3.6.3. Competitive Scenario
6.3.6.4. Regulatory Framework
6.3.6.5. Reimbursement Scenario
6.3.6.6. Italy Alzheimer’s Therapeutics Market, 2018 - 2030 (USD Million)
6.3.7. Spain
6.3.7.1. Key Country Dynamics
6.3.7.2. Target Disease Prevalence
6.3.7.3. Competitive Scenario
6.3.7.4. Regulatory Framework
6.3.7.5. Reimbursement Scenario
6.3.7.6. Spain Alzheimer’s Therapeutics Market, 2018 - 2030 (USD Million)
6.3.8. Denmark
6.3.8.1. Key Country Dynamics
6.3.8.2. Target Disease Prevalence
6.3.8.3. Competitive Scenario
6.3.8.4. Regulatory Framework
6.3.8.5. Reimbursement Scenario
6.3.8.6. Denmark Alzheimer’s Therapeutics Market, 2018 - 2030 (USD Million)
6.3.9. Sweden
6.3.9.1. Key Country Dynamics
6.3.9.2. Target Disease Prevalence
6.3.9.3. Competitive Scenario
6.3.9.4. Regulatory Framework
6.3.9.5. Reimbursement Scenario
6.3.9.6. Sweden Alzheimer’s Therapeutics Market, 2018 - 2030 (USD Million)
6.3.10. Norway
6.3.10.1. Key Country Dynamics
6.3.10.2. Target Disease Prevalence
6.3.10.3. Competitive Scenario
6.3.10.4. Regulatory Framework
6.3.10.5. Reimbursement Scenario
6.3.10.6. Norway Alzheimer’s Therapeutics Market, 2018 - 2030 (USD Million)
6.4. Asia Pacific
6.4.1. SWOT Analysis
6.4.2. Asia Pacific Alzheimer’s Therapeutics Market, 2018 - 2030 (USD Million)
6.4.3. Japan
6.4.3.1. Key Country Dynamics
6.4.3.2. Target Disease Prevalence
6.4.3.3. Competitive Scenario
6.4.3.4. Regulatory Framework
6.4.3.5. Reimbursement Scenario
6.4.3.6. Japan Alzheimer’s Therapeutics Market, 2018 - 2030 (USD Million)
6.4.4. China
6.4.4.1. Key Country Dynamics
6.4.4.2. Target Disease Prevalence
6.4.4.3. Competitive Scenario
6.4.4.4. Regulatory Framework
6.4.4.5. Reimbursement Scenario
6.4.4.6. China Alzheimer’s Therapeutics Market, 2018 - 2030 (USD Million)
6.4.5. India
6.4.5.1. Key Country Dynamics
6.4.5.2. Target Disease Prevalence
6.4.5.3. Competitive Scenario
6.4.5.4. Regulatory Framework
6.4.5.5. Reimbursement Scenario
6.4.5.6. India Alzheimer’s Therapeutics Market, 2018 - 2030 (USD Million)
6.4.6. South Korea
6.4.6.1. Key Country Dynamics
6.4.6.2. Target Disease Prevalence
6.4.6.3. Competitive Scenario
6.4.6.4. Regulatory Framework
6.4.6.5. Reimbursement Scenario
6.4.6.6. South Korea Alzheimer’s Therapeutics Market, 2018 - 2030 (USD Million)
6.4.7. Australia
6.4.7.1. Key Country Dynamics
6.4.7.2. Target Disease Prevalence
6.4.7.3. Competitive Scenario
6.4.7.4. Regulatory Framework
6.4.7.5. Reimbursement Scenario
6.4.7.6. Australia Alzheimer’s Therapeutics Market, 2018 - 2030 (USD Million)
6.4.8. Thailand
6.4.8.1. Key Country Dynamics
6.4.8.2. Target Disease Prevalence
6.4.8.3. Competitive Scenario
6.4.8.4. Regulatory Framework
6.4.8.5. Reimbursement Scenario
6.4.8.6. Thailand Alzheimer’s Therapeutics Market, 2018 - 2030 (USD Million)
6.5. Latin America
6.5.1. SWOT Analysis
6.5.2. Latin America Alzheimer’s Therapeutics Market, 2018 - 2030 (USD Million)
6.5.3. Brazil
6.5.3.1. Key Country Dynamics
6.5.3.2. Target Disease Prevalence
6.5.3.3. Competitive Scenario
6.5.3.4. Regulatory Framework
6.5.3.5. Reimbursement Scenario
6.5.3.6. Brazil Alzheimer’s Therapeutics Market, 2018 - 2030 (USD Million)
6.5.4. Mexico
6.5.4.1. Key Country Dynamics
6.5.4.2. Target Disease Prevalence
6.5.4.3. Competitive Scenario
6.5.4.4. Regulatory Framework
6.5.4.5. Reimbursement Scenario
6.5.4.6. Mexico Alzheimer’s Therapeutics Market, 2018 - 2030 (USD Million)
6.5.5. Argentina
6.5.5.1. Key Country Dynamics
6.5.5.2. Target Disease Prevalence
6.5.5.3. Competitive Scenario
6.5.5.4. Regulatory Framework
6.5.5.5. Reimbursement Scenario
6.5.5.6. Argentina Alzheimer’s Therapeutics Market, 2018 - 2030 (USD Million)
6.6. MEA
6.6.1. SWOT Analysis
6.6.2. MEA Alzheimer’s Therapeutics Market, 2018 - 2030 (USD Million)
6.6.3. South Africa
6.6.3.1. Key Country Dynamics
6.6.3.2. Target Disease Prevalence
6.6.3.3. Competitive Scenario
6.6.3.4. Regulatory Framework
6.6.3.5. Reimbursement Scenario
6.6.3.6. South Africa Alzheimer’s Therapeutics Market, 2018 - 2030 (USD Million)
6.6.4. Saudi Arabia
6.6.4.1. Key Country Dynamics
6.6.4.2. Target Disease Prevalence
6.6.4.3. Competitive Scenario
6.6.4.4. Regulatory Framework
6.6.4.5. Reimbursement Scenario
6.6.4.6. Saudi Arabia Alzheimer’s Therapeutics Market, 2018 - 2030 (USD Million)
6.6.5. UAE
6.6.5.1. Key Country Dynamics
6.6.5.2. Target Disease Prevalence
6.6.5.3. Competitive Scenario
6.6.5.4. Regulatory Framework
6.6.5.5. Reimbursement Scenario
6.6.5.6. UAE Alzheimer’s Therapeutics Market, 2018 - 2030 (USD Million)
6.6.6. Kuwait
6.6.6.1. Key Country Dynamics
6.6.6.2. Target Disease Prevalence
6.6.6.3. Competitive Scenario
6.6.6.4. Regulatory Framework
6.6.6.5. Reimbursement Scenario
6.6.6.6. Kuwait Alzheimer’s Therapeutics Market, 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1 Company Categorization
7.2 Strategy Mapping
7.2.1 New Product Launch
7.2.2 Partnerships
7.2.3 Acquisition
7.2.4 Collaboration
7.2.5 Funding
7.3 Key Company Market Share Analysis, 2022
7.4 Company Profiles
7.4.1 EISAI CO., LTD.
7.4.1.1 Company overview
7.4.1.2 Financial performance
7.4.1.3 Product benchmarking
7.4.1.4 Strategic Initiatives
7.4.2 NOVARTIS AG
7.4.2.1 Company overview
7.4.2.2 Financial performance
7.4.2.3 Product benchmarking
7.4.2.4 Strategic Initiatives
7.4.3 ABBVIE INC. (ALLERGAN PLC.)
7.4.3.1 Company overview
7.4.3.2 Financial performance
7.4.3.3 Product benchmarking
7.4.3.4 Strategic Initiatives
7.4.4 ADAMAS PHARMACEUTICALS, INC.
7.4.4.1 Company overview
7.4.4.2 Product benchmarking
7.4.4.3 Strategic Initiatives
7.4.5 H. LUNDBECK A/S
7.4.5.1 Company overview
7.4.5.2 Financial performance
7.4.5.3 Product benchmarking
7.4.5.4 Strategic Initiatives
7.4.6 BIOGEN
7.4.6.1 Company overview
7.4.6.2 Financial performance
7.4.6.3 Product benchmarking
7.4.6.4 Strategic Initiatives
7.4.7 AC IMMUNE
7.4.7.1 Company overview
7.4.7.2 Financial performance
7.4.7.3 Product benchmarking
7.4.7.4 Strategic Initiatives
7.4.8 F. HOFFMANN LA ROCHE LTD.
7.4.8.1 Company overview
7.4.8.2 Financial performance
7.4.8.3 Product benchmarking
7.4.8.4 Strategic Initiatives
7.4.9 DAIICHI SANKYO COMPANY, LIMITED
7.4.9.1 Company overview
7.4.9.2 Financial performance
7.4.9.3 Product benchmarking
7.4.9.4 Strategic Initiatives
7.4.10 JOHNSON & JOHNSON SERVICES, INC.
7.4.7.1 Company overview
7.4.7.2 Financial performance
7.4.7.3 Product benchmarking
7.4.7.4 Strategic Initiatives
List of Tables
Table 1: List of Secondary Sources
Table 2: List of Abbreviations
Table 3: Global Alzheimer’s Therapeutics Market, by Region, 2018-2030 (USD Million)
Table 4: Global Alzheimer’s Therapeutics Market, by Product, 2018-2030 (USD Million)
Table 5: Global Alzheimer’s Therapeutics Market, by End-user, 2018-2030 (USD Million)
Table 6: Global Alzheimer’s Therapeutics Market, by Region, 2018-2030 (USD Million)
Table 7: North America Alzheimer’s Therapeutics Market, by Country, 2018-2030 (USD Million)
Table 8: North America Alzheimer’s Therapeutics Market, by Product, 2018-2030 (USD Million)
Table 9: North America Alzheimer’s Therapeutics Market, by End-user, 2018-2030 (USD Million)
Table 10: U.S. Alzheimer’s Therapeutics Market, by Product, 2018-2030 (USD Million)
Table 11: U.S. Alzheimer’s Therapeutics Market, by End-user, 2018-2030 (USD Million)
Table 12: Canada Alzheimer’s Therapeutics Market, by Product, 2018-2030 (USD Million)
Table 13: Canada Alzheimer’s Therapeutics Market, by End-user, 2018-2030 (USD Million)
Table 14: Europe Alzheimer’s Therapeutics Market, by Country, 2018-2030 (USD Million)
Table 15: Europe Alzheimer’s Therapeutics Market, by Product, 2018-2030 (USD Million)
Table 16: Europe Alzheimer’s Therapeutics Market, by End-user, 2018-2030 (USD Million)
Table 17: Germany Alzheimer’s Therapeutics Market, by Product, 2018-2030 (USD Million)
Table 18: Germany Alzheimer’s Therapeutics Market, by End-user, 2018-2030 (USD Million)
Table 19: UK Alzheimer’s Therapeutics Market, by Product, 2018-2030 (USD Million)
Table 20: UK Alzheimer’s Therapeutics Market, by End-user, 2018-2030 (USD Million)
Table 21: France Alzheimer’s Therapeutics Market, by Product, 2018-2030 (USD Million)
Table 22: France Alzheimer’s Therapeutics Market, by End-user, 2018-2030 (USD Million)
Table 23: Italy Alzheimer’s Therapeutics Market, by Product, 2018-2030 (USD Million)
Table 24: Italy Alzheimer’s Therapeutics Market, by End-user, 2018-2030 (USD Million)
Table 25: Spain Alzheimer’s Therapeutics Market, by Product, 2018-2030 (USD Million)
Table 26: Spain Alzheimer’s Therapeutics Market, by End-user, 2018-2030 (USD Million)
Table 27: Denmark Alzheimer’s Therapeutics Market, by Product, 2018-2030 (USD Million)
Table 28: Denmark Alzheimer’s Therapeutics Market, by End-user, 2018-2030 (USD Million)
Table 29: Sweden Alzheimer’s Therapeutics Market, by Product, 2018-2030 (USD Million)
Table 30: Sweden Alzheimer’s Therapeutics Market, by End-user, 2018-2030 (USD Million)
Table 31: Norway Alzheimer’s Therapeutics Market, by Product, 2018-2030 (USD Million)
Table 32: Norway Alzheimer’s Therapeutics Market, by End-user, 2018-2030 (USD Million)
Table 33: Asia Pacific Alzheimer’s Therapeutics Market, by Country, 2018-2030 (USD Million)
Table 34: Asia Pacific Alzheimer’s Therapeutics Market, by Product, 2018-2030 (USD Million)
Table 35: Asia Pacific Alzheimer’s Therapeutics Market, by End-user, 2018-2030 (USD Million)
Table 36: China Alzheimer’s Therapeutics Market, by Product, 2018-2030 (USD Million)
Table 37: China Alzheimer’s Therapeutics Market, by End-user, 2018-2030 (USD Million)
Table 38: Japan Alzheimer’s Therapeutics Market, by Product, 2018-2030 (USD Million)
Table 39: Japan Alzheimer’s Therapeutics Market, by End-user, 2018-2030 (USD Million)
Table 40: India Alzheimer’s Therapeutics Market, by Product, 2018-2030 (USD Million)
Table 41: India Alzheimer’s Therapeutics Market, by End-user, 2018-2030 (USD Million)
Table 42: South Korea Alzheimer’s Therapeutics Market, by Product, 2018-2030 (USD Million)
Table 43: South Korea Alzheimer’s Therapeutics Market, by End-user, 2018-2030 (USD Million)
Table 44: Australia Alzheimer’s Therapeutics Market, by Product, 2018-2030 (USD Million)
Table 45: Australia Alzheimer’s Therapeutics Market, by End-user, 2018-2030 (USD Million)
Table 46: Thailand Alzheimer’s Therapeutics Market, by Product, 2018-2030 (USD Million)
Table 47: Thailand Alzheimer’s Therapeutics Market, by End-user, 2018-2030 (USD Million)
Table 48: Latin America Alzheimer’s Therapeutics Market, by Country, 2018-2030 (USD Million)
Table 49: Latin America Alzheimer’s Therapeutics Market, by Product, 2018-2030 (USD Million)
Table 50: Latin America Alzheimer’s Therapeutics Market, by End-user, 2018-2030 (USD Million)
Table 51: Brazil Alzheimer’s Therapeutics Market, by Product, 2018-2030 (USD Million)
Table 52: Brazil Alzheimer’s Therapeutics Market, by End-user, 2018-2030 (USD Million)
Table 53: Mexico Alzheimer’s Therapeutics Market, by Product, 2018-2030 (USD Million)
Table 54: Mexico Alzheimer’s Therapeutics Market, by End-user, 2018-2030 (USD Million)
Table 55: Argentina Alzheimer’s Therapeutics Market, by Product, 2018-2030 (USD Million)
Table 56: Argentina Alzheimer’s Therapeutics Market, by End-user, 2018-2030 (USD Million)
Table 57: Middle East & Africa Alzheimer’s Therapeutics Market, by Country, 2018-2030 (USD Million)
Table 58: Middle East & Africa Alzheimer’s Therapeutics Market, by Product, 2018-2030 (USD Million)
Table 59: Middle East & Africa Alzheimer’s Therapeutics Market, by End-user, 2018-2030 (USD Million)
Table 60: South Africa Alzheimer’s Therapeutics Market, by Product, 2018-2030 (USD Million)
Table 61: South Africa Alzheimer’s Therapeutics Market, by End-user, 2018-2030 (USD Million)
Table 62: Saudi Arabia Alzheimer’s Therapeutics Market, by Product, 2018-2030 (USD Million)
Table 63: Saudi Arabia Alzheimer’s Therapeutics Market, by End-user, 2018-2030 (USD Million)
Table 64: UAE Alzheimer’s Therapeutics Market, by Product, 2018-2030 (USD Million)
Table 65: UAE Alzheimer’s Therapeutics Market, by End-user, 2018-2030 (USD Million)
Table 66: Kuwait Alzheimer’s Therapeutics Market, by Product, 2018-2030 (USD Million)
Table 67: Kuwait Alzheimer’s Therapeutics Market, by End-user, 2018-2030 (USD Million)
List of Figures
Fig. 1: Market Research Process
Fig. 2: Information Procurement
Fig. 3: Primary Research Pattern
Fig. 4: Market Research Approaches
Fig. 5: Value Chain-Based Sizing & Forecasting
Fig. 6: Market Formulation & Validation
Fig. 7: Alzheimer’s Therapeutics Market Segmentation
Fig. 8: Market Snapshot, 2022
Fig. 9: Market Trends & Outlook
Fig. 10: Market Driver Relevance Analysis (Current & Future Impact)
Fig. 11: Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 12: SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 13: Porter’s Five Forces Analysis
Fig. 14: Global Alzheimer’s Therapeutics Market: by Product Movement Analysis
Fig. 15: Global Alzheimer’s Therapeutics Market, for Cholinesterase inhibitors, 2018-2030 (USD Million)
Fig. 16: Global Alzheimer’s Therapeutics Market, for Donepezil, 2018-2030 (USD Million)
Fig. 17: Global Alzheimer’s Therapeutics Market, for Galantamine, 2018-2030 (USD Million)
Fig. 18: Global Alzheimer’s Therapeutics Market, for Rivastigmine, 2018-2030 (USD Million)
Fig. 19: Global Alzheimer’s Therapeutics Market, for N-methyl-D-aspartate receptor antagonist, 2018-2030 (USD Million)
Fig. 20: Global Alzheimer’s Therapeutics Market, for Combination drug, 2018-2030 (USD Million)
Fig. 21: Global Alzheimer’s Therapeutics Market, for Pipeline drugs, 2018-2030 (USD Million)
Fig. 22: Global Alzheimer’s Therapeutics Market: End user Movement Analysis
Fig. 23: Global Alzheimer’s Therapeutics Market, for Pharmaceutical & Biotechnology Companies, 2018-2030 (USD Million)
Fig. 24: Global Alzheimer’s Therapeutics Market, for Hospital pharmacy, 2018-2030 (USD Million)
Fig. 25: Global Alzheimer’s Therapeutics Market, for Retail pharmacy, 2018-2030 (USD Million)
Fig. 26: Global Alzheimer’s Therapeutics Market, for E-commerce, 2018-2030 (USD Million)
Fig. 27: Regional Marketplace: Key Takeaways Alzheimer’s Therapeutics Market, Region 2018-2030 (USD Million)
Fig. 28: Alzheimer’s Therapeutics Market :Regional Outlook, 2022 & 2030 2018-2030 (USD Million)
Fig. 29: North America Alzheimer’s Therapeutics Market, 2018-2030 (USD Million)
Fig. 30: U.S. Alzheimer’s Therapeutics Market, 2018-2030 (USD Million)
Fig. 31: Canada Alzheimer’s Therapeutics Market, 2018-2030 (USD Million)
Fig. 32: Europe Alzheimer’s Therapeutics Market, 2018-2030 (USD Million)
Fig. 33: Germany Alzheimer’s Therapeutics Market, 2018-2030 (USD Million)
Fig. 34: UK Alzheimer’s Therapeutics Market, 2018-2030 (USD Million)
Fig. 35: France Alzheimer’s Therapeutics Market, 2018-2030 (USD Million)
Fig. 36: Italy Alzheimer’s Therapeutics Market, 2018-2030 (USD Million)
Fig. 37: Spain Alzheimer’s Therapeutics Market, 2018-2030 (USD Million)
Fig. 38: Denmark Alzheimer’s Therapeutics Market, 2018-2030 (USD Million)
Fig. 39: Sweden Alzheimer’s Therapeutics Market, 2018-2030 (USD Million)
Fig. 40: Norway Alzheimer’s Therapeutics Market, 2018-2030 (USD Million)
Fig. 41: Asia Pacific Alzheimer’s Therapeutics Market, 2018-2030 (USD Million)
Fig. 42: Japan Alzheimer’s Therapeutics Market, 2018-2030 (USD Million)
Fig. 43: China Alzheimer’s Therapeutics Market, 2018-2030 (USD Million)
Fig. 44: India Alzheimer’s Therapeutics Market, 2018-2030 (USD Million)
Fig. 45: Australia Alzheimer’s Therapeutics Market, 2018-2030 (USD Million)
Fig. 46: South Korea Alzheimer’s Therapeutics Market, 2018-2030 (USD Million)
Fig. 47: Thailand Alzheimer’s Therapeutics Market, 2018-2030 (USD Million)
Fig. 48: Latin America Alzheimer’s Therapeutics Market, 2018-2030 (USD Million)
Fig. 49: Brazil Alzheimer’s Therapeutics Market, 2018-2030 (USD Million)
Fig. 50: Mexico Alzheimer’s Therapeutics Market, 2018-2030 (USD Million)
Fig. 51: Argentina Alzheimer’s Therapeutics Market, 2018-2030 (USD Million)
Fig. 52: Middle East and Africa Alzheimer’s Therapeutics Market, 2018-2030 (USD Million)
Fig. 53: South Africa Alzheimer’s Therapeutics Market, 2018-2030 (USD Million)
Fig. 54: Saudi Arabia Alzheimer’s Therapeutics Market, 2018-2030 (USD Million)
Fig. 55: UAE Alzheimer’s Therapeutics Market, 2018-2030 (USD Million)
Fig. 56: Kuwait Alzheimer’s Therapeutics Market, 2018-2030 (USD Million)

Companies Mentioned

  • EISAI CO., LTD.
  • NOVARTIS AG
  • ABBVIE INC. (ALLERGAN PLC.)
  • ADAMAS PHARMACEUTICALS, INC.
  • H. LUNDBECK A/S
  • BIOGEN
  • AC IMMUNE
  • F. HOFFMANN LA ROCHE LTD.
  • DAIICHI SANKYO COMPANY, LIMITED
  • JOHNSON & JOHNSON SERVICES, INC.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Alzheimer's Therapeutics Market by Drug Class, Type, Distribution - Global Forecast 2025-2030 - Product Image

Alzheimer's Therapeutics Market by Drug Class, Type, Distribution - Global Forecast 2025-2030

  • Report
  • 183 Pages
  • Global
From
Alzheimer's Drugs Global Market Report 2024 - Product Image

Alzheimer's Drugs Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Alzheimer's Drugs Market Report by Drug Class, Drug Type, Distribution Channel, Region and Company Analysis 2024-2032 - Product Image

Alzheimer's Drugs Market Report by Drug Class, Drug Type, Distribution Channel, Region and Company Analysis 2024-2032

  • Report
  • 225 Pages
  • Global
From
Alzheimer's Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Alzheimer's Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 180 Pages
  • Global
From
Alzheimer's Drugs Market Report and Forecast 2024-2032 - Product Image

Alzheimer's Drugs Market Report and Forecast 2024-2032

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.